PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
16895698-1	2005	Adefovir is transported by the organic anion transporter (OAT1) and the multidrug resistant protein (MRP2, 4 and 5).	adefovir	0-8	solute carrier family 22 member 6	Rattus norvegicus	58-62
16895698-1	2005	Adefovir is transported by the organic anion transporter (OAT1) and the multidrug resistant protein (MRP2, 4 and 5).	adefovir	0-8	ATP binding cassette subfamily C member 2	Rattus norvegicus	101-114
15778544-7	2005	The median values of serum AST and ALT levels were significantly reduced from 86+/-80 IU/L and 140+/-103 IU/L, respectively before the adefovir administration to 42+/-19 IU/L and 38+/-33 IU/L after 2 months of administration.	adefovir	135-143	solute carrier family 17 member 5	Homo sapiens	27-30
15914676-8	2005	Interestingly, the K(m) for the nucleoside phosphonate analogs adefovir, cidofovir, and tenofovir seemed to be decreased in the R50H-hOAT1 variant compared with the wild type, whereas the kinetics of K525I-hOAT1 remained unchanged.	adefovir	63-71	solute carrier family 22 member 6	Homo sapiens	133-138
15864112-5	2005	A small family-based clinical study was conducted to determine the renal elimination of a model OAT1 substrate, adefovir (an antiviral agent) in human subjects who possessed a non-functional variant, OAT1-R454Q.	adefovir	112-120	solute carrier family 22 member 6	Homo sapiens	96-100
15864112-5	2005	A small family-based clinical study was conducted to determine the renal elimination of a model OAT1 substrate, adefovir (an antiviral agent) in human subjects who possessed a non-functional variant, OAT1-R454Q.	adefovir	112-120	solute carrier family 22 member 6	Homo sapiens	200-204
14762102-0	2004	Multidrug resistance protein (MRP) 4- and MRP 5-mediated efflux of 9-(2-phosphonylmethoxyethyl)adenine by microglia.	adefovir	67-102	ATP binding cassette subfamily C member 4	Rattus norvegicus	0-36
15450948-5	2004	Adefovir was more efficiently phosphorylated in primary hepatocytes than cell lines with adefovir-DP accounting for 44% versus 26% of total intracellular adefovir after 24 h. Egress studies showed adefovir-DP to have a half-life of 33 +/- 3 h, 10 +/- 1 h, 48 +/- 3 h and 33 +/- 2 h in Hep G2, Huh-7, and primary hepatocytes from two separate donors, respectively.	adefovir	0-8	MIR7-3 host gene	Homo sapiens	293-298
15546254-3	2004	Interferon-alfa and direct antiviral agents such as lamivudine and adefovir are effective in the therapy of chronic HBV infection but the efficacy is far from satisfactory, particularly in perinatally infected patients, patients with lower ALT levels and those with HBeAg-negative chronic hepatitis B. Thymalfasin (thymosin-alpha1) is an immunoregulatory agent able to enhance Th1 response.	adefovir	67-75	negative elongation factor complex member C/D	Homo sapiens	377-380
14762102-0	2004	Multidrug resistance protein (MRP) 4- and MRP 5-mediated efflux of 9-(2-phosphonylmethoxyethyl)adenine by microglia.	adefovir	67-102	ATP binding cassette subfamily C member 5	Rattus norvegicus	42-47
14762102-6	2004	Bis(pivaloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine [bis(POM)PMEA], a lipophilic ester prodrug of the well characterized MRP4 and 5 substrate 9-(2-phosphonylmethoxyethyl)adenine (PMEA), was chosen to examine transport characteristics in MLS-9.	adefovir	20-55	ATP binding cassette subfamily C member 4	Rattus norvegicus	125-129
14762102-6	2004	Bis(pivaloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine [bis(POM)PMEA], a lipophilic ester prodrug of the well characterized MRP4 and 5 substrate 9-(2-phosphonylmethoxyethyl)adenine (PMEA), was chosen to examine transport characteristics in MLS-9.	adefovir	65-69	ATP binding cassette subfamily C member 4	Rattus norvegicus	125-129
11802779-7	2002	ABCC4 also mediates resistance to purine analogues 9-(2-phosphonylmethoxyethyl)-adenine and 6-thioguanine.	adefovir	51-87	ATP binding cassette subfamily C member 4	Homo sapiens	0-5
12695538-4	2003	In cytotoxicity assays, MRP4 conferred resistance to the antiviral agent 9-(2-phosphonomethoxyethyl)adenine (PMEA) and high-performance liquid chromatography analysis showed that, like MRP5, MRP4 transported PMEA in an unmodified form.	adefovir	73-107	ATP binding cassette subfamily C member 4	Homo sapiens	24-28
12695538-4	2003	In cytotoxicity assays, MRP4 conferred resistance to the antiviral agent 9-(2-phosphonomethoxyethyl)adenine (PMEA) and high-performance liquid chromatography analysis showed that, like MRP5, MRP4 transported PMEA in an unmodified form.	adefovir	73-107	ATP binding cassette subfamily C member 5	Homo sapiens	185-189
12695538-4	2003	In cytotoxicity assays, MRP4 conferred resistance to the antiviral agent 9-(2-phosphonomethoxyethyl)adenine (PMEA) and high-performance liquid chromatography analysis showed that, like MRP5, MRP4 transported PMEA in an unmodified form.	adefovir	73-107	ATP binding cassette subfamily C member 4	Homo sapiens	191-195
12695538-4	2003	In cytotoxicity assays, MRP4 conferred resistance to the antiviral agent 9-(2-phosphonomethoxyethyl)adenine (PMEA) and high-performance liquid chromatography analysis showed that, like MRP5, MRP4 transported PMEA in an unmodified form.	adefovir	109-113	ATP binding cassette subfamily C member 4	Homo sapiens	24-28
12695538-4	2003	In cytotoxicity assays, MRP4 conferred resistance to the antiviral agent 9-(2-phosphonomethoxyethyl)adenine (PMEA) and high-performance liquid chromatography analysis showed that, like MRP5, MRP4 transported PMEA in an unmodified form.	adefovir	208-212	ATP binding cassette subfamily C member 4	Homo sapiens	24-28
32287463-6	2003	Adefovir dipivoxil has been approved in the United States and the European Union for the treatment of HBV, providing a second small molecule antiviral to add to lamivudine (3TC) and the injectable protein IFNalpha as the only approved agents for treating HBV infection.	adefovir	0-8	interferon alpha 1	Homo sapiens	205-213
12396448-8	2002	The dideoxynucleoside RTI abacavir as well as the phosphonates (R)-PMPA and PMEA were more active in infected MO-DCs as compared with either CEM T cells or PHA/IL-2 activated CD4(+) T cells.	adefovir	76-80	interleukin 2	Homo sapiens	160-164
12396448-8	2002	The dideoxynucleoside RTI abacavir as well as the phosphonates (R)-PMPA and PMEA were more active in infected MO-DCs as compared with either CEM T cells or PHA/IL-2 activated CD4(+) T cells.	adefovir	76-80	CD4 molecule	Homo sapiens	175-178
12396448-9	2002	Infection in cocultures of MO-DCs and autologous CD4(+) T cells could be aborted in a proportion of the cultures, with high concentrations of PMEA and/or efavirenz, but not with AZT.	adefovir	142-146	CD4 molecule	Homo sapiens	49-52
10991954-0	2000	Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1.	adefovir	90-98	solute carrier family 22 member 6	Homo sapiens	121-154
12423063-4	2002	We first identified, MRP4, based on its ability to efflux antiretroviral compounds, such as azidothymidine monophosphate (AZT-MP) and 9-(2-phosphonyl methoxyethyl) adenine (PMEA), in drug-resistant and also in transfected cell lines.	adefovir	134-171	ATP binding cassette subfamily C member 4	Homo sapiens	21-25
12423063-4	2002	We first identified, MRP4, based on its ability to efflux antiretroviral compounds, such as azidothymidine monophosphate (AZT-MP) and 9-(2-phosphonyl methoxyethyl) adenine (PMEA), in drug-resistant and also in transfected cell lines.	adefovir	173-177	ATP binding cassette subfamily C member 4	Homo sapiens	21-25
11804191-5	2001	MRP4 and MRP5 resemble each other more closely than they resemble MRPs 1-3 and confer resistance to purine and nucleotide analogs which are either inherently anionic, as in the case of the anti-AIDS drug PMEA, or are phosphorylated and converted to anionic amphiphiles in the cell, as in the case of 6-MP.	adefovir	204-208	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
11563082-2	2001	When expressed in CHO cells, hOAT1 mediates the uptake and cytotoxicity of ANPs suggesting that it plays an active role in the nephrotoxicity associated with cidofovir CMV therapy and high-dose adefovir HIV therapy.	adefovir	194-202	solute carrier family 22 member 6	Homo sapiens	29-34
10840050-3	2000	We found resistance against the thiopurine anticancer drugs, 6-mercaptopurine (6-MP) and thioguanine, and the anti-HIV drug 9-(2-phosphonylmethoxyethyl)adenine (PMEA) in MRP5-transfected cells.	adefovir	124-159	ATP binding cassette subfamily C member 5	Homo sapiens	170-174
10840050-4	2000	This resistance is due to an increased extrusion of PMEA and 6-thioinosine monophosphate from the cells that overproduce MRP5.	adefovir	52-56	ATP binding cassette subfamily C member 5	Homo sapiens	121-125
12012449-5	2002	To explain peculiar Raman features a "syn-like" conformation is suggested for N1-protonated PMEA species in aqueous solutions instead of an anti-like one adopted by H2PMEA in crystals or by common AMPs in aqueous solutions.	adefovir	92-96	synemin	Homo sapiens	38-41
11804191-5	2001	MRP4 and MRP5 resemble each other more closely than they resemble MRPs 1-3 and confer resistance to purine and nucleotide analogs which are either inherently anionic, as in the case of the anti-AIDS drug PMEA, or are phosphorylated and converted to anionic amphiphiles in the cell, as in the case of 6-MP.	adefovir	204-208	ATP binding cassette subfamily C member 5	Homo sapiens	9-13
11447229-2	2001	Human multidrug resistance protein 4 (MRP4) has recently been determined to confer resistance to the antiviral purine analog 9-(2-phosphonylmethoxyethyl)adenine and methotrexate.	adefovir	125-160	ATP binding cassette subfamily C member 4	Homo sapiens	6-36
11447229-2	2001	Human multidrug resistance protein 4 (MRP4) has recently been determined to confer resistance to the antiviral purine analog 9-(2-phosphonylmethoxyethyl)adenine and methotrexate.	adefovir	125-160	ATP binding cassette subfamily C member 4	Homo sapiens	38-42
11106685-13	2000	CONCLUSIONS: These results indicate that MRP4 confers resistance to short-term methotrexate and continuous PMEA treatment.	adefovir	107-111	ATP-binding cassette, sub-family C (CFTR/MRP), member 4	Mus musculus	41-45
10944550-7	2000	MRP4 overexpression is associated with high-level resistance to the nucleoside analogues 9-(2-phosphonylmethoxyethyl) adenine and azidothymidine, both of which are used as anti-human immunodeficiency virus drugs.	adefovir	89-125	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
10991954-3	2000	It has been recently shown that adefovir is efficiently transported by the human renal organic anion transporter 1 (hOAT1), a membrane transport protein localized in the kidney, that presumably mediates the accumulation of adefovir in renal proximal tubules.	adefovir	32-40	solute carrier family 22 member 6	Homo sapiens	81-114
10991954-3	2000	It has been recently shown that adefovir is efficiently transported by the human renal organic anion transporter 1 (hOAT1), a membrane transport protein localized in the kidney, that presumably mediates the accumulation of adefovir in renal proximal tubules.	adefovir	32-40	solute carrier family 22 member 6	Homo sapiens	116-121
10991954-3	2000	It has been recently shown that adefovir is efficiently transported by the human renal organic anion transporter 1 (hOAT1), a membrane transport protein localized in the kidney, that presumably mediates the accumulation of adefovir in renal proximal tubules.	adefovir	223-231	solute carrier family 22 member 6	Homo sapiens	81-114
10991954-3	2000	It has been recently shown that adefovir is efficiently transported by the human renal organic anion transporter 1 (hOAT1), a membrane transport protein localized in the kidney, that presumably mediates the accumulation of adefovir in renal proximal tubules.	adefovir	223-231	solute carrier family 22 member 6	Homo sapiens	116-121
10991954-4	2000	In an effort to look for novel inhibitors of this transport process, we used a cell line stably expressing hOAT1 to demonstrate that nonsteroidal anti-inflammatory drugs (NSAIDs) efficiently inhibit hOAT1-specific transport of adefovir at clinically relevant concentrations.	adefovir	227-235	solute carrier family 22 member 6	Homo sapiens	107-112
10991954-4	2000	In an effort to look for novel inhibitors of this transport process, we used a cell line stably expressing hOAT1 to demonstrate that nonsteroidal anti-inflammatory drugs (NSAIDs) efficiently inhibit hOAT1-specific transport of adefovir at clinically relevant concentrations.	adefovir	227-235	solute carrier family 22 member 6	Homo sapiens	199-204
10991954-6	2000	Importantly, NSAIDs significantly reduced the shift in adefovir cytotoxicity observed upon hOAT1 expression with ketoprofen and naproxen being 2- to 3-times more effective than probenecid.	adefovir	55-63	solute carrier family 22 member 6	Homo sapiens	91-96
10470083-6	1999	In our study of alternative or additional mechanisms of resistance operating during antiviral therapy, overexpression and amplification of the MRP4 gene correlated with ATP-dependent efflux of PMEA (9-(2-phosphonylmethoxyethyl)adenine) and azidothymidine monophosphate from cells and, thus, with resistance to these drugs.	adefovir	193-197	ATP binding cassette subfamily C member 4	Homo sapiens	143-147
10703662-0	2000	Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1.	adefovir	38-46	solute carrier family 22 member 6	Homo sapiens	99-132
10703662-2	2000	In addition to other anionic substrates, the human renal organic anion transporter 1 (hOATI) is capable of transporting the nucleotide analogs adefovir and cidofovir.	adefovir	143-151	solute carrier family 22 member 6	Homo sapiens	51-84
10462545-9	1999	The affinity of hOAT1 toward cidofovir and adefovir (K(m) = 46 and 30 microM, respectively) was 5- to 9-fold higher compared with rROAT1 (K(m) = 238 and 270 microM, respectively).	adefovir	43-51	solute carrier family 22 member 6	Homo sapiens	16-21
10462545-10	1999	These data indicate that hOAT1 may significantly contribute to the accumulation of cidofovir and adefovir in renal proximal tubules and, thus, play an active role in the mechanism of nephrotoxicity associated with these antiviral therapeutics.	adefovir	97-105	solute carrier family 22 member 6	Homo sapiens	25-30
10470083-6	1999	In our study of alternative or additional mechanisms of resistance operating during antiviral therapy, overexpression and amplification of the MRP4 gene correlated with ATP-dependent efflux of PMEA (9-(2-phosphonylmethoxyethyl)adenine) and azidothymidine monophosphate from cells and, thus, with resistance to these drugs.	adefovir	199-234	ATP binding cassette subfamily C member 4	Homo sapiens	143-147
10470083-7	1999	Overexpression of MRP4 mRNA and MRP4 protein severely impaired the antiviral efficacy of PMEA, azidothymidine and other nucleoside analogs.	adefovir	89-93	ATP binding cassette subfamily C member 4	Homo sapiens	18-22
10470083-7	1999	Overexpression of MRP4 mRNA and MRP4 protein severely impaired the antiviral efficacy of PMEA, azidothymidine and other nucleoside analogs.	adefovir	89-93	ATP binding cassette subfamily C member 4	Homo sapiens	32-36
10470083-8	1999	Increased resistance to PMEA and amplification of the MRP4 gene correlated with enhanced drug efflux; transfer of chromosome 13 containing the amplified MRP4 gene conferred resistance to PMEA.	adefovir	187-191	ATP binding cassette subfamily C member 4	Homo sapiens	153-157
10440094-9	1999	Under the same conditions PMEA inhibits, while PMPA slightly stimulates, secretion of RANTES.	adefovir	26-30	C-C motif chemokine ligand 5	Rattus norvegicus	86-92
11364624-0	1997	Adefovir dipivoxil trials: CD4 100-500, protease inhibitor naive.	adefovir	0-8	CD4 molecule	Homo sapiens	27-30
10392905-1	1999	In addition to its inhibitory activity against viral DNA polymerases and reverse transcriptase, the acyclic nucleoside phosphonate 9-(2-phosphonylmethoxyethyl)adenine (PMEA) also markedly inhibits the replicative cellular DNA polymerases alpha, delta, and epsilon.	adefovir	131-166	DNA polymerase alpha 1, catalytic subunit	Homo sapiens	222-263
10392905-1	1999	In addition to its inhibitory activity against viral DNA polymerases and reverse transcriptase, the acyclic nucleoside phosphonate 9-(2-phosphonylmethoxyethyl)adenine (PMEA) also markedly inhibits the replicative cellular DNA polymerases alpha, delta, and epsilon.	adefovir	168-172	DNA polymerase alpha 1, catalytic subunit	Homo sapiens	222-263
10392905-9	1999	On the contrary, THP-1 cells underwent apoptotic cell death in the presence of PMEA, as demonstrated by prelytic, intracellular DNA fragmentation and the binding of annexin V to the cell surface.	adefovir	79-83	annexin A5	Homo sapiens	165-174
10462545-0	1999	The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1.	adefovir	47-55	solute carrier family 22 member 6	Rattus norvegicus	95-128
10462545-8	1999	Importantly, both hOAT1 and rat renal organic anion transporter 1 (rROAT1) mediated saturable, probenecid-sensitive uptake of cidofovir, adefovir, and other nucleoside phosphonate antivirals.	adefovir	137-145	solute carrier family 22 member 6	Homo sapiens	18-23
10462545-8	1999	Importantly, both hOAT1 and rat renal organic anion transporter 1 (rROAT1) mediated saturable, probenecid-sensitive uptake of cidofovir, adefovir, and other nucleoside phosphonate antivirals.	adefovir	137-145	solute carrier family 22 member 6	Rattus norvegicus	32-65
10462545-8	1999	Importantly, both hOAT1 and rat renal organic anion transporter 1 (rROAT1) mediated saturable, probenecid-sensitive uptake of cidofovir, adefovir, and other nucleoside phosphonate antivirals.	adefovir	137-145	solute carrier family 22 member 6	Rattus norvegicus	67-73
10069380-4	1999	The effect of 9-(2-phosphonylmethoxyethyl)adenine on de novo (thymidylate synthase-mediated) and salvage (thymidine kinase-mediated) dTTP synthesis was investigated using radio-labelled nucleoside precursors.	adefovir	14-49	thymidylate synthetase	Homo sapiens	62-82
10069380-5	1999	The amount of thymidylate synthase-derived dTTP in the acid soluble pool was 2-4-fold higher in PMEA-treated than in untreated K562 cells, which is in accord with the 3-4-fold expansion of the global dTTP level in the presence of 9-(2-phosphonylmethoxyethyl)adenine.	adefovir	96-100	thymidylate synthetase	Homo sapiens	14-34
10069380-5	1999	The amount of thymidylate synthase-derived dTTP in the acid soluble pool was 2-4-fold higher in PMEA-treated than in untreated K562 cells, which is in accord with the 3-4-fold expansion of the global dTTP level in the presence of 9-(2-phosphonylmethoxyethyl)adenine.	adefovir	230-265	thymidylate synthetase	Homo sapiens	14-34
10069380-8	1999	Also, in the presence of 200 microM 9-(2-phosphonylmethoxyethyl)adenine, 14-fold less thymidylate synthase-derived but only 3-fold less thymidine kinase-derived dTTP was incorporated into the DNA of the K562 cells.	adefovir	36-71	thymidylate synthetase	Homo sapiens	86-106
34431452-6	2021	While, adefovir, a nucleotide HBV DNA polymerase inhibitor exhibited good dock score and binding interactions against RdRp.	adefovir	7-15	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	118-122
7511362-7	1994	Dose-dependent enhancement of NK activity and IFN production could also be demonstrated during chronic administration of PMEA (more resembling to what will be the schedule of administration of this drug in patients).	adefovir	121-125	interferon alpha 1	Homo sapiens	46-49
24478474-3	2014	For this study, a multiplex ligation-dependent probe real-time PCR (MLP-RT-PCR) method was developed to simultaneously detect lamivudine (LAM)- and adefovir (ADV)-resistant HBV mutants (those with the mutations rtM204V/I, rtA181V/T, and rtN236T).	adefovir	148-156	cysteine and glycine rich protein 3	Homo sapiens	68-71
24478474-3	2014	For this study, a multiplex ligation-dependent probe real-time PCR (MLP-RT-PCR) method was developed to simultaneously detect lamivudine (LAM)- and adefovir (ADV)-resistant HBV mutants (those with the mutations rtM204V/I, rtA181V/T, and rtN236T).	adefovir	158-161	cysteine and glycine rich protein 3	Homo sapiens	68-71
33344505-1	2020	Molecular dynamics (MD) simulations have been recorded on the complex between the edema factor (EF) of Bacilllus anthracis and calmodulin (CaM), starting from a structure with the orthosteric inhibitor adefovir bound in the EF catalytic site.	adefovir	202-210	calmodulin 1	Homo sapiens	127-137
34805481-12	2021	Our results evidently demonstrate that cephalosporins and nucleotide analogues (especially acyclic nucleotide analogues such as adefovir and cidofovir) are computationally potent agonists of TLR7.	adefovir	128-136	toll like receptor 7	Homo sapiens	191-195
35114312-1	2022	Organic anion transporters 1 (OAT1) and OAT3 are responsible for transporting adefovir (ADV) into renal tubular epithelial cells.	adefovir	78-86	solute carrier family 22 member 6	Rattus norvegicus	0-28
35114312-1	2022	Organic anion transporters 1 (OAT1) and OAT3 are responsible for transporting adefovir (ADV) into renal tubular epithelial cells.	adefovir	78-86	solute carrier family 22 member 6	Rattus norvegicus	30-34
35114312-1	2022	Organic anion transporters 1 (OAT1) and OAT3 are responsible for transporting adefovir (ADV) into renal tubular epithelial cells.	adefovir	78-86	solute carrier family 22 member 8	Rattus norvegicus	40-44
35114312-1	2022	Organic anion transporters 1 (OAT1) and OAT3 are responsible for transporting adefovir (ADV) into renal tubular epithelial cells.	adefovir	88-91	solute carrier family 22 member 6	Rattus norvegicus	0-28
35114312-1	2022	Organic anion transporters 1 (OAT1) and OAT3 are responsible for transporting adefovir (ADV) into renal tubular epithelial cells.	adefovir	88-91	solute carrier family 22 member 6	Rattus norvegicus	30-34
35114312-1	2022	Organic anion transporters 1 (OAT1) and OAT3 are responsible for transporting adefovir (ADV) into renal tubular epithelial cells.	adefovir	88-91	solute carrier family 22 member 8	Rattus norvegicus	40-44
35114312-5	2022	Results indicate that ADV triggers chymase release from cultured RBL-2H3 mast cells in a time-and concentration-dependent manner.	adefovir	22-25	chymase 1	Rattus norvegicus	35-42
35114312-7	2022	The concentrations of Ang II and fibrosis was significantly increased after administration of ADV alone or with probenecid for 4 weeks.	adefovir	94-97	angiotensinogen	Rattus norvegicus	22-28
33344505-1	2020	Molecular dynamics (MD) simulations have been recorded on the complex between the edema factor (EF) of Bacilllus anthracis and calmodulin (CaM), starting from a structure with the orthosteric inhibitor adefovir bound in the EF catalytic site.	adefovir	202-210	calmodulin 1	Homo sapiens	139-142
33344505-2	2020	The starting structure has been destabilized by alternately suppressing different co-factors, such as adefovir ligand or ions, revealing several long-distance correlations between the conformation of CaM, the geometry of the CaM/EF interface, the enzymatic site and the overall organization of the complex.	adefovir	102-110	calmodulin 1	Homo sapiens	200-203
33344505-2	2020	The starting structure has been destabilized by alternately suppressing different co-factors, such as adefovir ligand or ions, revealing several long-distance correlations between the conformation of CaM, the geometry of the CaM/EF interface, the enzymatic site and the overall organization of the complex.	adefovir	102-110	calmodulin 1	Homo sapiens	225-228
32840739-13	2020	In conclusion, this is an unusual ADV-resistant HBV isolate harboring two nonsense mutations in the S gene and a large in-frame deletion in the preS1 region, but still retains a high replication phenotype, which can provide a platform for recombinant vector construction.	adefovir	34-37	large envelope protein;middle envelope protein;small envelope protein	Hepatitis B virus	144-149
30971673-0	2019	[Marked improvement in renal tubular markers after switching from adefovir to tenofovir alafenamide in a case of Fanconi syndrome diagnosed through high ALP levels].	adefovir	66-74	ATHS	Homo sapiens	153-156
30872078-0	2019	Adefovir dipivoxil sensitizes colon cancer cells to vemurafenib by disrupting the KCTD12-CDK1 interaction.	adefovir	0-8	potassium channel tetramerization domain containing 12	Homo sapiens	82-88
30872078-0	2019	Adefovir dipivoxil sensitizes colon cancer cells to vemurafenib by disrupting the KCTD12-CDK1 interaction.	adefovir	0-8	cyclin dependent kinase 1	Homo sapiens	89-93
32159854-0	2020	Adefovir dipivoxil induces DNA replication stress and augments ATR inhibitor related cytotoxicity.	adefovir	0-8	ATR serine/threonine kinase	Homo sapiens	63-66
30610118-7	2019	Pharmacological inhibition of C/EBPbeta expression with the antiviral drug adefovir dipivoxil attenuated TGFbeta-mediated activation of LX-2 or primary rat HSCs in vitro and hepatic fibrogenesis in vivo Finally, we identified a critical relationship between C/EBPbeta and the transcriptional regulator p300 during HSC activation.	adefovir	75-83	CCAAT/enhancer binding protein beta	Rattus norvegicus	30-39
30610118-7	2019	Pharmacological inhibition of C/EBPbeta expression with the antiviral drug adefovir dipivoxil attenuated TGFbeta-mediated activation of LX-2 or primary rat HSCs in vitro and hepatic fibrogenesis in vivo Finally, we identified a critical relationship between C/EBPbeta and the transcriptional regulator p300 during HSC activation.	adefovir	75-83	transforming growth factor, beta 1	Rattus norvegicus	105-112
30610118-7	2019	Pharmacological inhibition of C/EBPbeta expression with the antiviral drug adefovir dipivoxil attenuated TGFbeta-mediated activation of LX-2 or primary rat HSCs in vitro and hepatic fibrogenesis in vivo Finally, we identified a critical relationship between C/EBPbeta and the transcriptional regulator p300 during HSC activation.	adefovir	75-83	CCAAT/enhancer binding protein beta	Rattus norvegicus	258-267
30610118-7	2019	Pharmacological inhibition of C/EBPbeta expression with the antiviral drug adefovir dipivoxil attenuated TGFbeta-mediated activation of LX-2 or primary rat HSCs in vitro and hepatic fibrogenesis in vivo Finally, we identified a critical relationship between C/EBPbeta and the transcriptional regulator p300 during HSC activation.	adefovir	75-83	fucosyltransferase 1 (H blood group)	Homo sapiens	156-159
30467540-8	2018	Furthermore, the FNG molecules adsorbed on the surface of PMEA were easily desorbed, even in the polymer-rich domains.	adefovir	58-62	fibrinogen beta chain	Homo sapiens	17-20
28960749-3	2018	Efflux of [3 H]-9-(2-phosphonomethoxyethyl) adenine ([3 H]-PMEA), a known ABCC4 substrate in humans, was detected from PhABCC4 cRNA-injected oocytes by liquid scintillation spectrophotometric analysis and PhABCC4 expression in oocytes was confirmed using ABC transporter inhibitors.	adefovir	59-63	ATP binding cassette subfamily C member 4	Homo sapiens	74-79
28198412-8	2017	The drug Adefovir Dipivoxil passed all counter assays and increases fatty acid beta-oxidation in a hepatoma cell line in a LIP-dependent manner.	adefovir	9-17	CCAAT/enhancer binding protein (C/EBP), beta	Mus musculus	123-126
27789659-6	2018	RESULTS: Higher serum IFN-lambda3 levels were detected in the patients treated with nucleotide analogues (adefovir or tenofovir) compared with those treated with nucleoside analogues (lamivudine or entecavir).	adefovir	106-114	interferon lambda 3	Homo sapiens	22-33
30372692-13	2018	Expression of MRP4, a nucleoside transporter, appeared to influence the response of AML cells to ODE-adefovir, as its inhibition potentiated ODE-adefovir killing.	adefovir	101-109	ATP binding cassette subfamily C member 4	Homo sapiens	14-18
28397817-0	2017	Tenofovir and adefovir down-regulate mitochondrial chaperone TRAP1 and succinate dehydrogenase subunit B to metabolically reprogram glucose metabolism and induce nephrotoxicity.	adefovir	14-22	TNF receptor associated protein 1	Homo sapiens	61-66
28397817-0	2017	Tenofovir and adefovir down-regulate mitochondrial chaperone TRAP1 and succinate dehydrogenase subunit B to metabolically reprogram glucose metabolism and induce nephrotoxicity.	adefovir	14-22	succinate dehydrogenase complex iron sulfur subunit B	Homo sapiens	71-104
27858892-1	2016	The aim of this study was to evaluate serum kidney injury molecule-1 (KIM-1) as a new diagnostic marker of renal dysfunction in chronic hepatitis B (CHB) patients receiving long-term adefovir dipivoxil (ADV) treatment.We retrospectively enrolled 85 patients treated with ADV and 85 patients treated with entecavir (ETV) monotherapy, for at least 6 months.	adefovir	183-191	hepatitis A virus cellular receptor 1	Homo sapiens	44-68
27858892-1	2016	The aim of this study was to evaluate serum kidney injury molecule-1 (KIM-1) as a new diagnostic marker of renal dysfunction in chronic hepatitis B (CHB) patients receiving long-term adefovir dipivoxil (ADV) treatment.We retrospectively enrolled 85 patients treated with ADV and 85 patients treated with entecavir (ETV) monotherapy, for at least 6 months.	adefovir	183-191	hepatitis A virus cellular receptor 1	Homo sapiens	70-75
27155352-16	2016	Higher IP-10 levels at baseline seem to be associated with CR in HBeAg-positive patients treated with peginterferon and adefovir, but not in HBeAg-negative patients.	adefovir	120-128	C-X-C motif chemokine ligand 10	Homo sapiens	7-12
26164128-0	2016	Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48-week result.	adefovir	63-71	capsid protein;pre-capsid protein	Hepatitis B virus	95-100
26779022-7	2015	ETV inhibited the cellular uptake of adefovir, tenofovir, and cidofovir by hOAT1; however, effective inhibition was shown at ETV concentrations exceeding therapeutic levels.	adefovir	37-45	solute carrier family 22 member 6	Homo sapiens	75-80
26821801-11	2016	Functional OAT1 was directly responsible for cytotoxicity of adefovir, cidofovir, and tenofovir, while a drug interaction with zidovudine was not associated with decreased cell viability.	adefovir	61-69	solute carrier family 22 member 6	Homo sapiens	11-15
27301512-0	2016	Urinary beta-2 Microglobulin Levels Sensitively Altered in an Osteomalacia Patient Receiving Add-on Adefovir Dipivoxil Therapy for Hepatitis B Virus Infection.	adefovir	100-108	beta-2-microglobulin	Homo sapiens	8-28
25536518-5	2015	We observed intracellular accumulation of adefovir in hypoxia and suggest decreases in the efflux transport proteins MRP4, MRP5, NHERF1 and NHERF3 as a possible explanation.	adefovir	42-50	PDZ domain containing 1	Homo sapiens	140-146
25892855-9	2015	After treatment with adefovir, the frequency of CD95 and IgD expressed on B cells was increased in HBV patients.	adefovir	21-29	Fas cell surface death receptor	Homo sapiens	48-52
25448811-3	2015	We show here that three antiviral drugs, adefovir, cidofovir and tenofovir exhibit significantly increased cytotoxicity in HEK293 cells transfected with organic anion transporter (OAT) 1 and 3 compared to a lack of cytotoxicity in HEK293 wildtype cells.	adefovir	41-49	solute carrier family 22 member 6	Homo sapiens	153-192
24436471-6	2014	When expressed in HEK293 cells, NHERF3 increased membrane expression of MRP4 by reducing internalization of cell surface MRP4 and consequently, augmented MRP4-mediated efflux of adefovir, a nucleoside-based antiviral agent and well known substrate of MRP4.	adefovir	178-186	PDZ domain containing 1	Homo sapiens	32-38
25674464-4	2014	At 4-hr exposure HEK/MRP4 cells were 2-4-fold resistant to troxacitabine, ara-C and 9-(2-phosphonylmethoxyethyl)adenine (PMEA), and HEK/MRP5i to ara-C and PMEA, but none to GEM.	adefovir	84-119	ATP binding cassette subfamily C member 4	Homo sapiens	21-25
25674464-4	2014	At 4-hr exposure HEK/MRP4 cells were 2-4-fold resistant to troxacitabine, ara-C and 9-(2-phosphonylmethoxyethyl)adenine (PMEA), and HEK/MRP5i to ara-C and PMEA, but none to GEM.	adefovir	121-125	ATP binding cassette subfamily C member 4	Homo sapiens	21-25
25674464-4	2014	At 4-hr exposure HEK/MRP4 cells were 2-4-fold resistant to troxacitabine, ara-C and 9-(2-phosphonylmethoxyethyl)adenine (PMEA), and HEK/MRP5i to ara-C and PMEA, but none to GEM.	adefovir	155-159	ATP binding cassette subfamily C member 4	Homo sapiens	21-25
25320730-1	2014	BACKGROUND/AIMS: Adefovir (ADV) and lamivudine (LAM) combination therapy (ADV+LAM) has been a useful option for patients with LAM-resistant (LAM-r) chronic hepatitis B (CHB).	adefovir	17-25	ribosomal protein SA	Homo sapiens	126-131
24747579-2	2014	Based on published data, adefovir and benzylpenicillin were selected as organic anion transporter (OAT) 1- and OAT3-selective probe substrates, respectively.	adefovir	25-33	solute carrier family 22 member 6	Homo sapiens	72-105
24747579-2	2014	Based on published data, adefovir and benzylpenicillin were selected as organic anion transporter (OAT) 1- and OAT3-selective probe substrates, respectively.	adefovir	25-33	solute carrier family 22 member 8	Homo sapiens	111-115
24747579-9	2014	These results suggest that adefovir and benzylpenicillin can be used as probe drugs for OAT1 and OAT3, respectively, and that PAH can be used to investigate the role of OAT1 in the urinary excretion of drugs in humans, whereas it may modulate other transport processes in the kidney.	adefovir	27-35	solute carrier family 22 member 6	Homo sapiens	88-92
24747579-9	2014	These results suggest that adefovir and benzylpenicillin can be used as probe drugs for OAT1 and OAT3, respectively, and that PAH can be used to investigate the role of OAT1 in the urinary excretion of drugs in humans, whereas it may modulate other transport processes in the kidney.	adefovir	27-35	solute carrier family 22 member 8	Homo sapiens	97-101
24957831-13	2014	AmB-DOC interacted significantly with adefovir, tenofovir, and cidofovir in hOAT1-transfected cells at supratherapeutic concentrations.	adefovir	38-46	solute carrier family 22 member 6	Homo sapiens	76-81
25091927-4	2014	The phosphonate was shown to be a moderate but selective substrate of the mitochondrial human AK2, better than well-known antiviral acyclic phosphonates 9-(2-phosphonomethoxyethyl)adenine (PMEA, Adefovir) and (R)-9-(2-phosphonomethoxypropyl)adenine (PMPA, Tenofovir).	adefovir	153-187	adenylate kinase 2	Homo sapiens	94-97
25091927-4	2014	The phosphonate was shown to be a moderate but selective substrate of the mitochondrial human AK2, better than well-known antiviral acyclic phosphonates 9-(2-phosphonomethoxyethyl)adenine (PMEA, Adefovir) and (R)-9-(2-phosphonomethoxypropyl)adenine (PMPA, Tenofovir).	adefovir	189-193	adenylate kinase 2	Homo sapiens	94-97
25091927-4	2014	The phosphonate was shown to be a moderate but selective substrate of the mitochondrial human AK2, better than well-known antiviral acyclic phosphonates 9-(2-phosphonomethoxyethyl)adenine (PMEA, Adefovir) and (R)-9-(2-phosphonomethoxypropyl)adenine (PMPA, Tenofovir).	adefovir	195-203	adenylate kinase 2	Homo sapiens	94-97
24436471-6	2014	When expressed in HEK293 cells, NHERF3 increased membrane expression of MRP4 by reducing internalization of cell surface MRP4 and consequently, augmented MRP4-mediated efflux of adefovir, a nucleoside-based antiviral agent and well known substrate of MRP4.	adefovir	178-186	ATP binding cassette subfamily C member 4	Homo sapiens	72-76
24436471-6	2014	When expressed in HEK293 cells, NHERF3 increased membrane expression of MRP4 by reducing internalization of cell surface MRP4 and consequently, augmented MRP4-mediated efflux of adefovir, a nucleoside-based antiviral agent and well known substrate of MRP4.	adefovir	178-186	ATP binding cassette subfamily C member 4	Homo sapiens	121-125
24436471-6	2014	When expressed in HEK293 cells, NHERF3 increased membrane expression of MRP4 by reducing internalization of cell surface MRP4 and consequently, augmented MRP4-mediated efflux of adefovir, a nucleoside-based antiviral agent and well known substrate of MRP4.	adefovir	178-186	ATP binding cassette subfamily C member 4	Homo sapiens	121-125
24436471-6	2014	When expressed in HEK293 cells, NHERF3 increased membrane expression of MRP4 by reducing internalization of cell surface MRP4 and consequently, augmented MRP4-mediated efflux of adefovir, a nucleoside-based antiviral agent and well known substrate of MRP4.	adefovir	178-186	ATP binding cassette subfamily C member 4	Homo sapiens	121-125
23406845-2	2013	The aim of this study is to determine the effect of the addition of adefovir (ADV) in hepatitis B e antigen (HBeAg)-positive CHB patients with VBT or resistance to LdT.	adefovir	68-76	capsid protein;pre-capsid protein	Hepatitis B virus	109-114
24085784-7	2013	Total and percent of CD5 + B cells gradually decreased following the diminution of the HBV DNA load after tenofovir and adefovir treatment.	adefovir	120-128	CD5 molecule	Homo sapiens	21-24
23775562-8	2013	In contrast, targeted inactivation of Abcc4/Mrp4 in mouse cells specifically enhanced nelfinavir and 9-(2-phosphonylmethoxyethyl) adenine cytotoxicity.	adefovir	101-137	ATP-binding cassette, sub-family C (CFTR/MRP), member 4	Mus musculus	38-43
23775562-8	2013	In contrast, targeted inactivation of Abcc4/Mrp4 in mouse cells specifically enhanced nelfinavir and 9-(2-phosphonylmethoxyethyl) adenine cytotoxicity.	adefovir	101-137	ATP-binding cassette, sub-family C (CFTR/MRP), member 4	Mus musculus	44-48
23775562-10	2013	Because nelfinavir is a new MRP4/ABCC4 substrate, we developed a MRP4/ABCC4 pharmacophore model, which showed that the nelfinavir binding site is shared with chemotherapeutic substrates such as adefovir and methotrexate.	adefovir	194-202	ATP binding cassette subfamily C member 4	Homo sapiens	28-32
23775562-10	2013	Because nelfinavir is a new MRP4/ABCC4 substrate, we developed a MRP4/ABCC4 pharmacophore model, which showed that the nelfinavir binding site is shared with chemotherapeutic substrates such as adefovir and methotrexate.	adefovir	194-202	ATP binding cassette subfamily C member 4	Homo sapiens	33-38
23775562-10	2013	Because nelfinavir is a new MRP4/ABCC4 substrate, we developed a MRP4/ABCC4 pharmacophore model, which showed that the nelfinavir binding site is shared with chemotherapeutic substrates such as adefovir and methotrexate.	adefovir	194-202	ATP binding cassette subfamily C member 4	Homo sapiens	65-69
23775562-10	2013	Because nelfinavir is a new MRP4/ABCC4 substrate, we developed a MRP4/ABCC4 pharmacophore model, which showed that the nelfinavir binding site is shared with chemotherapeutic substrates such as adefovir and methotrexate.	adefovir	194-202	ATP binding cassette subfamily C member 4	Homo sapiens	70-75
23583281-0	2013	Reversible increase in FGF23 in a hypophosphatemic renal and bone disease linked to antiviral therapy by adefovir.	adefovir	105-113	fibroblast growth factor 23	Homo sapiens	23-28
23406845-2	2013	The aim of this study is to determine the effect of the addition of adefovir (ADV) in hepatitis B e antigen (HBeAg)-positive CHB patients with VBT or resistance to LdT.	adefovir	78-81	capsid protein;pre-capsid protein	Hepatitis B virus	109-114
23304062-5	2012	In adefovir group, NK cell numbers did not differ during the treatment, but also accompanied by downregulated expression of NKG2A and KIR2DL3.	adefovir	3-11	killer cell lectin like receptor C1	Homo sapiens	124-129
23458523-1	2013	The objective of this study was to compare the efficacy and safety of two rescue strategies for hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) patients with resistance to adefovir dipivoxil (ADV).	adefovir	189-197	capsid protein;pre-capsid protein	Hepatitis B virus	119-124
22132702-4	2012	Using presteady state kinetic techniques, we have measured the substrate specificity values for human DNA polymerases beta, lambda, eta, iota, kappa, and Rev1 incorporating the active forms of the following anti-HBV nucleoside analogues approved for clinical use: adefovir, tenofovir, lamivudine, telbivudine, and entecavir.	adefovir	264-272	endothelin receptor type A	Homo sapiens	119-122
22132702-4	2012	Using presteady state kinetic techniques, we have measured the substrate specificity values for human DNA polymerases beta, lambda, eta, iota, kappa, and Rev1 incorporating the active forms of the following anti-HBV nucleoside analogues approved for clinical use: adefovir, tenofovir, lamivudine, telbivudine, and entecavir.	adefovir	264-272	REV1 DNA directed polymerase	Homo sapiens	154-158
21993835-0	2012	Adefovir dipivoxil modulates cytokine expression in Th1/Th2 cells in             patients with chronic hepatitis B.	adefovir	0-8	negative elongation factor complex member C/D	Homo sapiens	52-55
22516125-1	2012	The spin crossover (SCO) compound [Fe(pmea)(NCS)(2)] (where pmea symbolizes the ligand bis[(2-pyridyl)methyl]-2-(2-pyridyl)ethylamine) has been studied by DFT/TD-DFT methods.	adefovir	38-42	spindlin 1	Homo sapiens	4-8
22387228-1	2012	Effects of 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3), natural ligand of the VDR, on the fates of adefovir dipivoxil (P-gp substrate) and its metabolites, mono(POM)-PMEA and adefovir (MRP4 substrate), were investigated in Caco-2 cells.	adefovir	99-107	phosphoglycolate phosphatase	Homo sapiens	119-123
23304062-5	2012	In adefovir group, NK cell numbers did not differ during the treatment, but also accompanied by downregulated expression of NKG2A and KIR2DL3.	adefovir	3-11	killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 3	Homo sapiens	134-141
21633528-6	2011	In the 13 hepatitis B patients who were treated and responded to adefovir dipivoxil, proportions of CD8+CD38+ T cells decreased from 53.9% +- 18.4% pre-therapy to 20.1% +- 11.3% by week 72 (P < 0.001), concomitant with viral load decline (HBV DNA fell from 7.31 to 3 log copies/mL).	adefovir	65-73	CD8a molecule	Homo sapiens	100-103
21320001-22	2011	In the patient receiving Adefovir, a known nephrotoxic drug, two of the three biomarkers (urinary albumin/gCr and NAG/gCr) increased, most notably NAG/gCr.	adefovir	25-33	nuclear receptor subfamily 3 group C member 1	Homo sapiens	106-109
21320001-22	2011	In the patient receiving Adefovir, a known nephrotoxic drug, two of the three biomarkers (urinary albumin/gCr and NAG/gCr) increased, most notably NAG/gCr.	adefovir	25-33	O-GlcNAcase	Homo sapiens	114-117
21320001-22	2011	In the patient receiving Adefovir, a known nephrotoxic drug, two of the three biomarkers (urinary albumin/gCr and NAG/gCr) increased, most notably NAG/gCr.	adefovir	25-33	nuclear receptor subfamily 3 group C member 1	Homo sapiens	118-121
21320001-22	2011	In the patient receiving Adefovir, a known nephrotoxic drug, two of the three biomarkers (urinary albumin/gCr and NAG/gCr) increased, most notably NAG/gCr.	adefovir	25-33	O-GlcNAcase	Homo sapiens	147-150
21320001-22	2011	In the patient receiving Adefovir, a known nephrotoxic drug, two of the three biomarkers (urinary albumin/gCr and NAG/gCr) increased, most notably NAG/gCr.	adefovir	25-33	nuclear receptor subfamily 3 group C member 1	Homo sapiens	118-121
21567420-8	2011	Increased compared to stable/decreased total apoptotic trend [D-apoptosis: (D-bax)-(D-bcl-xL)], was associated with worsening fibrosis, particularly in adefovir treated patients (D-stage: 2.3 vs. 0, P = 0.004).	adefovir	152-160	BCL2 associated X, apoptosis regulator	Homo sapiens	78-81
21567420-8	2011	Increased compared to stable/decreased total apoptotic trend [D-apoptosis: (D-bax)-(D-bcl-xL)], was associated with worsening fibrosis, particularly in adefovir treated patients (D-stage: 2.3 vs. 0, P = 0.004).	adefovir	152-160	BCL2 like 1	Homo sapiens	86-92
21633528-6	2011	In the 13 hepatitis B patients who were treated and responded to adefovir dipivoxil, proportions of CD8+CD38+ T cells decreased from 53.9% +- 18.4% pre-therapy to 20.1% +- 11.3% by week 72 (P < 0.001), concomitant with viral load decline (HBV DNA fell from 7.31 to 3 log copies/mL).	adefovir	65-73	CD38 molecule	Homo sapiens	104-108
21244849-11	2011	In addition, quercetin-3"-O-sulfate was shown to effectively reduce OAT1-mediated cytotoxicity of adefovir, an antiviral drug, in a dose-dependent manner.	adefovir	98-106	solute carrier family 22 member 6	Homo sapiens	68-72
21244849-0	2011	Flavonoid conjugates interact with organic anion transporters (OATs) and attenuate cytotoxicity of adefovir mediated by organic anion transporter 1 (OAT1/SLC22A6).	adefovir	99-107	solute carrier family 22 member 6	Homo sapiens	149-153
21351588-2	2010	Adefovir bis (L-amino acid) ester was used as lead compound, according to pathological and pharmacological findings that non-steroidal anti-inflammatory drugs can effectively inhibit the organic anion transporter 1 (hOAT1)-mediated adefovir phosphonic acid pairs of anion transport across tubular basement membrane thereby reducing the nephrotoxicity of adefovir.	adefovir	232-240	solute carrier family 22 member 6	Homo sapiens	187-214
21244849-2	2011	In this study, we examined the interaction between metabolites of quercetin and isoflavonoids found in vivo with human organic anion transporters 1 (OAT1) and 3 (OAT3) and their potential in attenuating OAT-induced cytotoxicity of adefovir.	adefovir	231-239	solute carrier family 22 member 6	Homo sapiens	119-147
21244849-2	2011	In this study, we examined the interaction between metabolites of quercetin and isoflavonoids found in vivo with human organic anion transporters 1 (OAT1) and 3 (OAT3) and their potential in attenuating OAT-induced cytotoxicity of adefovir.	adefovir	231-239	solute carrier family 22 member 6	Homo sapiens	149-153
21244849-2	2011	In this study, we examined the interaction between metabolites of quercetin and isoflavonoids found in vivo with human organic anion transporters 1 (OAT1) and 3 (OAT3) and their potential in attenuating OAT-induced cytotoxicity of adefovir.	adefovir	231-239	solute carrier family 22 member 8	Homo sapiens	162-166
21685538-9	2011	In patients with breakthroughs, K-18 fragment levels had only a trend towards a decrease from adefovir addition (198 U/l [124-1,219]) to 6 months (170 U/l [122-1,576]; P=0.109) and mainly to 12 months (156 U/l [122-878]; P=0.055).	adefovir	94-102	keratin 18	Homo sapiens	32-36
21161015-4	2010	Three years after the start of additional adefovir treatment, hepatocellular carcinoma (HCC) was detected and the patient underwent a successful hepatectomy.	adefovir	42-50	HCC	Homo sapiens	62-92
21161015-5	2010	Our findings suggest that the addition of adefovir to ongoing lamivudine therapy cannot completely suppress hepatocarcinogenesis, but is useful for improving liver function in patients with lamivudine-resistant HBV-related cirrhosis, allowing HCC surgery.	adefovir	42-50	HCC	Homo sapiens	243-246
20562676-5	2010	Salvage treatment with adefovir or entecavir was well tolerated, and resulted in a three-log decrease in hepatitis B deoxynucleic acid after 6 months and normalization of alanine aminotransferase in 75% of patients.	adefovir	23-31	glutamic--pyruvic transaminase	Homo sapiens	171-195
21401599-6	2011	KEY FINDINGS: A new solid adefovir dipivoxil-saccharin cocrystal with unique melting point, DSC, FTIR and XRPD data was obtained.	adefovir	26-34	desmocollin 3	Homo sapiens	92-95
21950152-1	2011	A rapid, sensitive and reproducible HPLC method was developed and validated for the analysis of adefovir (CAS 106941-25-7) in human plasma.	adefovir	96-104	BCAR1 scaffold protein, Cas family member	Homo sapiens	106-109
21351588-2	2010	Adefovir bis (L-amino acid) ester was used as lead compound, according to pathological and pharmacological findings that non-steroidal anti-inflammatory drugs can effectively inhibit the organic anion transporter 1 (hOAT1)-mediated adefovir phosphonic acid pairs of anion transport across tubular basement membrane thereby reducing the nephrotoxicity of adefovir.	adefovir	232-240	solute carrier family 22 member 6	Homo sapiens	216-221
19199343-9	2009	Cisplatin, zidovudine and adefovir were found to increase the levels of MCM mRNA and EGFP expression, providing support for the possible efficacy of these pharmacological compounds in treating methylmalonic aciduria.	adefovir	26-34	methylmalonyl-CoA mutase	Homo sapiens	72-75
19735648-0	2010	Role of basolateral efflux transporter MRP4 in the intestinal absorption of the antiviral drug adefovir dipivoxil.	adefovir	95-103	ATP binding cassette subfamily C member 4	Homo sapiens	39-43
19735648-10	2010	A comparison of these data with the reduction in the basolateral egress of adefovir by the general MRP inhibitor indomethacin established that MRP4, among MRPs, plays a predominant role in the basolateral egress of adefovir in Caco-2 cells.	adefovir	75-83	ATP binding cassette subfamily C member 1	Homo sapiens	99-102
19735648-10	2010	A comparison of these data with the reduction in the basolateral egress of adefovir by the general MRP inhibitor indomethacin established that MRP4, among MRPs, plays a predominant role in the basolateral egress of adefovir in Caco-2 cells.	adefovir	75-83	ATP binding cassette subfamily C member 4	Homo sapiens	143-147
19735648-10	2010	A comparison of these data with the reduction in the basolateral egress of adefovir by the general MRP inhibitor indomethacin established that MRP4, among MRPs, plays a predominant role in the basolateral egress of adefovir in Caco-2 cells.	adefovir	215-223	ATP binding cassette subfamily C member 1	Homo sapiens	99-102
19735648-10	2010	A comparison of these data with the reduction in the basolateral egress of adefovir by the general MRP inhibitor indomethacin established that MRP4, among MRPs, plays a predominant role in the basolateral egress of adefovir in Caco-2 cells.	adefovir	215-223	ATP binding cassette subfamily C member 4	Homo sapiens	143-147
19788684-9	2010	HCC developed more frequently in the patients with than without cirrhosis at the start of adefovir (10/59 [16.9%] vs. 8/188 [4.3%], P = 0.002).	adefovir	90-98	HCC	Homo sapiens	0-3
19788684-10	2010	CONCLUSION: HCC can develop in cirrhotic patients receiving adefovir add-on lamivudine.	adefovir	60-68	HCC	Homo sapiens	12-15
20025289-0	2010	Pressure effects on a spin-crossover monomeric compound [Fe(pmea)(SCN)(2)] (pmea = bis[(2-pyridyl)methyl]-2-(2-pyridyl)ethylamine).	adefovir	60-64	sorcin	Homo sapiens	66-69
19222742-1	2009	The aims of the study were to investigate the efficacy of rescue therapy with lamivudine (LAM) and adefovir (ADV) combination for 6 months followed by ADV monotherapy in lamivudine-resistant chronic hepatitis B (LAM-R CHB) patients, and to analyze the frequency of ADV resistance mutant development in such patients.	adefovir	99-107	ribosomal protein SA	Homo sapiens	212-217
19222742-1	2009	The aims of the study were to investigate the efficacy of rescue therapy with lamivudine (LAM) and adefovir (ADV) combination for 6 months followed by ADV monotherapy in lamivudine-resistant chronic hepatitis B (LAM-R CHB) patients, and to analyze the frequency of ADV resistance mutant development in such patients.	adefovir	109-112	ribosomal protein SA	Homo sapiens	212-217
19788684-1	2010	AIM: To identify factors for the development of hepatocellular carcinoma (HCC) in the patients who receive adefovir add-on lamivudine for treatment of lamivudine-resistant hepatitis B virus (HBV) mutants.	adefovir	107-115	HCC	Homo sapiens	74-77
21127728-5	2010	Adefovir dipivoxil treatment led to the increase of Th1/Th2 cytokines producing T cells and serum cytokine levels in association with the decline of HVB DNA load.	adefovir	0-8	negative elongation factor complex member C/D	Homo sapiens	52-55
19323627-9	2009	MRP5 inhibitors also diminished PMEA and acyclovir efflux.	adefovir	32-36	ATP binding cassette subfamily C member 5	Homo sapiens	0-4
19118001-3	2009	Here, it is shown by the analysis of MRP7-transfected HEK293 cells that, in addition to natural product agents, MRP7 is also able to confer resistance to nucleoside-based agents, such as the anticancer agents cytarabine (Ara-C) and gemcitabine, and the antiviral agents 2",3"-dideoxycytidine and PMEA.	adefovir	296-300	ATP binding cassette subfamily C member 10	Homo sapiens	37-41
19028678-10	2009	This suggested that OAT1 activity was also modified by PKCzeta, subsequently confirmed using an OAT1-specific substrate, adefovir.	adefovir	121-129	solute carrier family 22 (organic anion transporter), member 6	Mus musculus	20-24
19028678-10	2009	This suggested that OAT1 activity was also modified by PKCzeta, subsequently confirmed using an OAT1-specific substrate, adefovir.	adefovir	121-129	solute carrier family 22 (organic anion transporter), member 6	Mus musculus	96-100
19430092-2	2009	The goal of this study was to verify the usefulness of the roadmap concept to predict clinical outcomes of adefovir dipivoxil monotherapy in hepatitis B e antigen (HBeAg)-positive patients with lamivudine resistance.	adefovir	107-115	capsid protein;pre-capsid protein	Hepatitis B virus	164-169
19118001-3	2009	Here, it is shown by the analysis of MRP7-transfected HEK293 cells that, in addition to natural product agents, MRP7 is also able to confer resistance to nucleoside-based agents, such as the anticancer agents cytarabine (Ara-C) and gemcitabine, and the antiviral agents 2",3"-dideoxycytidine and PMEA.	adefovir	296-300	ATP binding cassette subfamily C member 10	Homo sapiens	112-116
19118001-4	2009	Consistent with the operation of an efflux pump, expression of MRP7 reduced the accumulation of Ara-C and PMEA.	adefovir	106-110	ATP binding cassette subfamily C member 10	Homo sapiens	63-67
18559527-6	2008	Increased plasma membrane MRP4 was accompanied by increased efflux function as reflected by reduced cellular accumulation of the MRP4 substrates 6-mercaptopurine and 9-[2-(phosphonylmethoxy)ethyl]-adenine.	adefovir	166-204	ATP binding cassette subfamily C member 4	Homo sapiens	26-30
17980137-0	2007	[Adefovir in reactivation of chemotherapy-induced hepatitis B in an anti-Hbc-positive patient].	adefovir	1-9	keratin 88, pseudogene	Homo sapiens	73-76
18364470-6	2008	The function of MRP4 variants was compared by measuring the intracellular accumulation of two antiviral agents, azidothymidine (AZT) and adefovir (PMEA).	adefovir	137-145	ATP binding cassette subfamily C member 4	Homo sapiens	16-20
18364470-6	2008	The function of MRP4 variants was compared by measuring the intracellular accumulation of two antiviral agents, azidothymidine (AZT) and adefovir (PMEA).	adefovir	147-151	ATP binding cassette subfamily C member 4	Homo sapiens	16-20
18364470-10	2008	However, two variants (G187W and G487E) showed a significantly reduced function compared to reference with both substrates, as evidenced by higher intracellular accumulation of AZT and PMEA compared to the reference MRP4 (43 and 69% increase in accumulation for G187W compared with the reference MRP4, with AZT and PMEA, respectively).	adefovir	185-189	ATP binding cassette subfamily C member 4	Homo sapiens	216-220
18364470-10	2008	However, two variants (G187W and G487E) showed a significantly reduced function compared to reference with both substrates, as evidenced by higher intracellular accumulation of AZT and PMEA compared to the reference MRP4 (43 and 69% increase in accumulation for G187W compared with the reference MRP4, with AZT and PMEA, respectively).	adefovir	185-189	ATP binding cassette subfamily C member 4	Homo sapiens	296-300
18364470-10	2008	However, two variants (G187W and G487E) showed a significantly reduced function compared to reference with both substrates, as evidenced by higher intracellular accumulation of AZT and PMEA compared to the reference MRP4 (43 and 69% increase in accumulation for G187W compared with the reference MRP4, with AZT and PMEA, respectively).	adefovir	315-319	ATP binding cassette subfamily C member 4	Homo sapiens	296-300
18461199-1	2008	Density functional calculations have been carried out on the experimentally characterized Co(III) [Co(N4)(O2CO)]+ carbonate complexes containing a tripodal tetraamine ligand (N4 = tpa, Metpa, Me2tpa, Me3tpa, pmea, pmap, tepa) and also the model [Co(NH3)4(O2CO)]+ system.	adefovir	208-212	mitochondrially encoded cytochrome c oxidase III	Homo sapiens	90-97
18174163-5	2008	Of nine common antiviral drugs assessed in oocytes, many manifested higher affinity for SLC22a6 (mOat1), originally identified as NKT (e.g. adefovir and cidofovir), two (ddC and ddI) manifested significantly higher affinity for mOat3, while mOat6 had comparatively low but measurable affinity for certain antivirals.	adefovir	140-148	solute carrier family 22 (organic anion transporter), member 6 S homeolog	Xenopus laevis	88-95
18174163-5	2008	Of nine common antiviral drugs assessed in oocytes, many manifested higher affinity for SLC22a6 (mOat1), originally identified as NKT (e.g. adefovir and cidofovir), two (ddC and ddI) manifested significantly higher affinity for mOat3, while mOat6 had comparatively low but measurable affinity for certain antivirals.	adefovir	140-148	solute carrier family 22 (organic anion transporter), member 6	Mus musculus	97-102
17638908-2	2007	An unexpectedly low concentration of the purine nucleotide analogue, 9-(2-(phosphonomethoxy)ethyl)-adenine (PMEA), and up-regulation of Abcg2 in some tissues of the Mrp4 KO mouse prompted us to evaluate the possibility that Abcg2 might transport purine-derived drugs.	adefovir	69-106	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	224-229
17638908-2	2007	An unexpectedly low concentration of the purine nucleotide analogue, 9-(2-(phosphonomethoxy)ethyl)-adenine (PMEA), and up-regulation of Abcg2 in some tissues of the Mrp4 KO mouse prompted us to evaluate the possibility that Abcg2 might transport purine-derived drugs.	adefovir	108-112	prolactin family 2, subfamily c, member 5	Mus musculus	165-169
16857889-4	2006	In contrast, 2,4-dichlorophenoxyacetic acid and adefovir are better transported by mammalian OAT1/Oat1 than by the OAT3/Oat3 clones.	adefovir	48-56	solute carrier family 22 member 6	Homo sapiens	93-97
17638908-2	2007	An unexpectedly low concentration of the purine nucleotide analogue, 9-(2-(phosphonomethoxy)ethyl)-adenine (PMEA), and up-regulation of Abcg2 in some tissues of the Mrp4 KO mouse prompted us to evaluate the possibility that Abcg2 might transport purine-derived drugs.	adefovir	108-112	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	224-229
17638908-4	2007	Moreover, a specific Abcg2 inhibitor, fumitremorgin C, both increased PMEA accumulation and reversed Abcg2-mediated PMEA resistance.	adefovir	70-74	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	21-26
17638908-4	2007	Moreover, a specific Abcg2 inhibitor, fumitremorgin C, both increased PMEA accumulation and reversed Abcg2-mediated PMEA resistance.	adefovir	116-120	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	21-26
17638908-4	2007	Moreover, a specific Abcg2 inhibitor, fumitremorgin C, both increased PMEA accumulation and reversed Abcg2-mediated PMEA resistance.	adefovir	116-120	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	101-106
17638908-6	2007	Abcg2 contributed to PMEA accumulation in a variety of tissues, but in some tissues, this contribution was only revealed by the concurrent absence of Mrp4.	adefovir	21-25	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-5
17218162-1	2007	Conventional treatment of chronic hepatitis B with interferon alfa-2b, lamivudine, and adefovir is limited by low rates of sustained hepatitis B virus DNA suppression and hepatitis B e antigen (HBeAg) seroconversion, increasing rates of drug resistance to the oral agents, and poor tolerability of interferon.	adefovir	87-95	capsid protein;pre-capsid protein	Hepatitis B virus	171-200
17210706-5	2007	In the absence of alterations in plasma PMEA levels, Mrp4-null mice treated with PMEA exhibit increased lethality associated with marked toxicity in several tissues.	adefovir	81-85	ATP-binding cassette, sub-family C (CFTR/MRP), member 4	Mus musculus	53-57
17210706-7	2007	In addition, PMEA penetration into the brain is increased in Mrp4(-/-) mice.	adefovir	13-17	ATP-binding cassette, sub-family C (CFTR/MRP), member 4	Mus musculus	61-65
17372702-0	2007	Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2).	adefovir	19-27	solute carrier family 22 member 6	Homo sapiens	80-85
17372702-0	2007	Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2).	adefovir	19-27	solute carrier family 22 member 8	Homo sapiens	87-92
17372702-0	2007	Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2).	adefovir	19-27	solute carrier family 22 member 2	Homo sapiens	98-103
17372702-5	2007	RESULTS: The uptake of adefovir, cidofovir and tenofovir in monolayers stably expressing hOAT3 increased time-dependently, compared with control.	adefovir	23-31	solute carrier family 22 member 8	Homo sapiens	89-94
17372702-9	2007	CONCLUSION: These results indicate that adefovir, cidofovir and tenofovir are substrates of hOAT3 as well as hOAT1, but that quantitatively hOAT1 is the major renal transporter for these drugs.	adefovir	40-48	solute carrier family 22 member 8	Homo sapiens	92-97
17372702-9	2007	CONCLUSION: These results indicate that adefovir, cidofovir and tenofovir are substrates of hOAT3 as well as hOAT1, but that quantitatively hOAT1 is the major renal transporter for these drugs.	adefovir	40-48	solute carrier family 22 member 6	Homo sapiens	109-114
17110501-0	2007	Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir.	adefovir	129-137	ATP-binding cassette, sub-family C (CFTR/MRP), member 4	Mus musculus	69-73
17110501-0	2007	Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir.	adefovir	129-137	ATP-binding cassette, sub-family C (CFTR/MRP), member 4	Mus musculus	74-79
17110501-3	2007	ATP-dependent uptake of adefovir and tenofovir but not cidofovir was observed only in the membrane vesicles expressing MRP4.	adefovir	24-32	ATP-binding cassette, sub-family C (CFTR/MRP), member 4	Mus musculus	119-123
17110501-4	2007	The ATP-dependent uptake of adefovir and tenofovir by MRP4 was not saturated at 1 mM.	adefovir	28-36	ATP-binding cassette, sub-family C (CFTR/MRP), member 4	Mus musculus	54-58
17110501-5	2007	The ATP-dependent uptake of adefovir by membrane vesicles expressing MRP4 was osmotic-sensitive.	adefovir	28-36	ATP-binding cassette, sub-family C (CFTR/MRP), member 4	Mus musculus	69-73
17110501-8	2007	The kidney accumulation of adefovir and tenofovir was significantly greater in Mrp4 knockout mice (130 versus 66 and 191 versus 87 pmol/g tissue, respectively); thus, the renal luminal efflux clearance was estimated to be 37 and 46%, respectively, of the control.	adefovir	27-35	ATP-binding cassette, sub-family C (CFTR/MRP), member 4	Mus musculus	79-83
17110501-12	2007	Our results suggest that MRP4 is involved in the luminal efflux of both adefovir and tenofovir, but it makes only a limited contribution to the urinary excretion of cidofovir.	adefovir	72-80	ATP-binding cassette, sub-family C (CFTR/MRP), member 4	Mus musculus	25-29
16868766-8	2007	Similar to the case for other MRPs that possess only two membrane spanning domains (MRP4 and MRP5), MRP8 is a cyclic nucleotide efflux pump that is able to confer resistance to nucleoside-based agents, such as PMEA and 5FU.	adefovir	210-214	ATP binding cassette subfamily C member 4	Homo sapiens	84-88
16868766-8	2007	Similar to the case for other MRPs that possess only two membrane spanning domains (MRP4 and MRP5), MRP8 is a cyclic nucleotide efflux pump that is able to confer resistance to nucleoside-based agents, such as PMEA and 5FU.	adefovir	210-214	ATP binding cassette subfamily C member 5	Homo sapiens	93-97
16868766-8	2007	Similar to the case for other MRPs that possess only two membrane spanning domains (MRP4 and MRP5), MRP8 is a cyclic nucleotide efflux pump that is able to confer resistance to nucleoside-based agents, such as PMEA and 5FU.	adefovir	210-214	ATP binding cassette subfamily C member 11	Homo sapiens	100-104
16857889-4	2006	In contrast, 2,4-dichlorophenoxyacetic acid and adefovir are better transported by mammalian OAT1/Oat1 than by the OAT3/Oat3 clones.	adefovir	48-56	solute carrier family 22 member 6	Homo sapiens	98-102
16857889-4	2006	In contrast, 2,4-dichlorophenoxyacetic acid and adefovir are better transported by mammalian OAT1/Oat1 than by the OAT3/Oat3 clones.	adefovir	48-56	solute carrier family 22 member 8	Homo sapiens	115-119
16857889-4	2006	In contrast, 2,4-dichlorophenoxyacetic acid and adefovir are better transported by mammalian OAT1/Oat1 than by the OAT3/Oat3 clones.	adefovir	48-56	solute carrier family 22 member 8	Homo sapiens	120-124
16756973-1	2006	Adefovir is transported by the organic anion transporter (OAT1) and the multidrug resistant protein (MRP2, 4 and 5).	adefovir	0-8	solute carrier family 22 member 6	Rattus norvegicus	58-62
17159773-9	2006	As the inhibitor concentration in the systemic circulation does not exceed 2 microM, the probability of a significant in vivo effect of adefovir, tenofovir and the respective prodrugs on the microsomal system of cytochromes P450 and FMO3 is relatively low.	adefovir	136-144	flavin containing dimethylaniline monoxygenase 3	Homo sapiens	233-237
17162464-4	2006	The activity of CYP3A4 was inhibited by adefovir dipivoxil at concentrations over 100 microM.	adefovir	40-48	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	16-22
17162464-5	2006	Adefovir and its prodrug inhibited CYP2C9 at concentrations below 100 microM; inhibition by adefovir was of the uncompetitive (at the lower inhibitor concentrations) or of the competitive nature with a Ki = 420 microM.	adefovir	0-8	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	35-41
16940083-1	2006	Metabolic activation of pradefovir to 9-(2-phosphonylmethoxyethyl)adenine (PMEA) was evaluated by using cDNA-expressed CYP isozymes in portal vein-cannulated rats following oral administration and in human liver microsomes.	adefovir	38-73	peptidylprolyl isomerase G	Homo sapiens	119-122
16940083-1	2006	Metabolic activation of pradefovir to 9-(2-phosphonylmethoxyethyl)adenine (PMEA) was evaluated by using cDNA-expressed CYP isozymes in portal vein-cannulated rats following oral administration and in human liver microsomes.	adefovir	75-79	peptidylprolyl isomerase G	Homo sapiens	119-122
16940083-3	2006	The results indicated that CYP3A4 is the only cDNA-expressed CYP isozyme catalyzing the conversion of pradefovir to PMEA.	adefovir	116-120	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	27-33
16940083-3	2006	The results indicated that CYP3A4 is the only cDNA-expressed CYP isozyme catalyzing the conversion of pradefovir to PMEA.	adefovir	116-120	peptidylprolyl isomerase G	Homo sapiens	27-30
16756973-1	2006	Adefovir is transported by the organic anion transporter (OAT1) and the multidrug resistant protein (MRP2, 4 and 5).	adefovir	0-8	ATP binding cassette subfamily C member 2	Rattus norvegicus	101-114